Combination of amphotericin B and flucytosine against neurotropic species of melanized fungi causing Primary cerebral phaeohyphomycosis

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 4, 2016, Pages 2346-2351

  Deng, S ^a,b   Pan, W ^a   Liao, W ^a   De Hoog, G S ^c,d,e   Van Den Ende, A H G Gerrits ^c,d   Vitale, R G ^f,g   Rafati, H ^h   Ilkit, M ⁱ   Van Der Lee, A H ^j   Rijs, A J M M ^j   Verweij, P E ^j   Seyedmousavi, S ^h,j,k  

^a SECOND MILITARY MEDICAL UNIVERSITY   (China)

^b XINJIANG MEDICAL UNIVERSITY   (China)

^c CBS KNAW FUNGAL BIODIVERSITY CENTRE   (Netherlands)

^d UNIVERSITY OF AMSTERDAM   (Netherlands)

^e KING ABDULAZIZ UNIVERSITY   (Saudi Arabia)

^f Conicet ^*  (Argentina)

^g HOSPITAL RAMOS MEJÍA   (Argentina)

^h ERASMUS MEDICAL CENTER   (Netherlands)

ⁱ CUKUROVA UNIVERSITY   (Turkey)

^j RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^k MAZANDARAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

more..

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; FLUCYTOSINE; ANTIFUNGAL AGENT; CULTURE MEDIUM; DRUG COMBINATION;

ANTIFUNGAL ACTIVITY; ARTICLE; BRAIN ABSCESS; CEREBRAL PHAEOHYPHOMYCOSIS; CHAETOTHYRIALES; CLADOPHIALOPHORA BANTIANA; DRUG POTENTIATION; EXOPHIALA DERMATITIDIS; IN VITRO STUDY; INHIBITORY CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; PRIORITY JOURNAL; BUDDING YEAST; CHEMISTRY; CULTURE MEDIUM; DRUG COMBINATION; DRUG EFFECTS; EXOPHIALA; FACTOR ANALYSIS; GROWTH, DEVELOPMENT AND AGING; HUMAN; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; PATHOGENICITY; PATHOLOGY;

AMPHOTERICIN B; ANTIFUNGAL AGENTS; CEREBRAL PHAEOHYPHOMYCOSIS; CULTURE MEDIA; DRUG COMBINATIONS; DRUG SYNERGISM; EXOPHIALA; FACTOR ANALYSIS, STATISTICAL; FLUCYTOSINE; HUMANS; MICROBIAL SENSITIVITY TESTS; SACCHAROMYCETALES;

EID: 84963737623     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.02526-15     Document Type: Article

References (49)

1. Chakrabarti A, Kaur H, Rudramurthy SM, Appannanavar SB, Patel A, Mukherjee KK, Ghosh A, Ray U. 2016. Brain abscess due to Cladophialophora bantiana: a review of 124 cases. Med Mycol 54:111-119. http://dx.doi.org/10.1093/mmy/myv091.
2. Li DM, de Hoog GS. 2009. Cerebral phaeohyphomycosis-a cure at what lengths? Lancet Infect Dis 9:376-383. http://dx.doi.org/10.1016/S1473-3099 (09) 70131-8.
3. De Hoog GS, Queiroz-Telles F, Haase G, Fernandez-Zeppenfeldt G, Attili Angelis D, Gerrits Van Den Ende AH, Matos T, Peltroche-Llacsahuanga H, Pizzirani-Kleiner AA, Rainer J, Richard-Yegres N, Vicente V, Yegres F. 2000. Black fungi: clinical and pathogenic approaches. Med Mycol 38(Suppl 1):S243-S250.
4. Kantarcioglu AS, de Hoog GS. 2004. Infections of the central nervous system by melanized fungi: a review of cases presented between 1999 and 2004. Mycoses 47:4-13. http://dx.doi.org/10.1046/j.1439-0507.2003.00956.x.
5. Horre R, De Hoog GS. 1999. Primary cerebral infections by melanized fungi: a review. Stud Mycol 43:176-193.
6. Surash S, Tyagi A, De Hoog GS, Zeng JS, Barton RC, Hobson RP. 2005. Cerebral phaeohyphomycosis caused by Fonsecaea monophora. Med Mycol 43:465-472. http://dx.doi.org/10.1080/13693780500220373.
7. Revankar SG, Sutton DA, Rinaldi MG. 2004. Primary central nervous system phaeohyphomycosis:a reviewof 101 cases. Clin Infect Dis 38:206-216. http://dx.doi.org/10.1086/380635.
8. Al-Abdely HM, Najvar LK, Bocanegra R, Graybill JR. 2005. Antifungal therapy of experimental cerebral phaeohyphomycosis due to Cladophialophora bantiana. Antimicrob Agents Chemother 49:1701-1707. http://dx.doi.org/10.1128/AAC.49.5.1701-1707.2005.
9. Al-Abdely HM, Najvar L, Bocanegra R, Fothergill A, Loebenberg D, Rinaldi MG, Graybill JR. 2000. SCH 56592, amphotericin B, or itraconazole therapy of experimental murine cerebral phaeohyphomycosis due to Ramichloridium obovoideum ("Ramichloridium mackenziei"). Antimicrob Agents Chemother 44:1159-1162. http://dx.doi.org/10.1128/AAC.44.5.1159-1162.2000.
10. Revankar SG. 2011. Cladophialophora bantiana brain abscess in an immunocompetent patient. Can J Infect Dis Med Microbiol 22:149-150.
11. Al-Abdely HM, Alkhunaizi AM, Al-Tawfiq JA, Hassounah M, Rinaldi MG, Sutton DA. 2005. Successful therapy of cerebral phaeohyphomycosis due to Ramichloridium mackenziei with the new triazole posaconazole. Med Mycol 43:91-95. http://dx.doi.org/10.1080/13693780400011104.
12. Mariné M, Pastor FJ, Guarro J. 2009. Combined antifungal therapy in a murine model of disseminated infection by Cladophialophora bantiana. Med Mycol 47:45-49. http://dx.doi.org/10.1080/13693780802526840.
13. Chowdhary A, Meis JF, Guarro J, de Hoog GS, Kathuria S, Arendrup MC, Arikan-Akdagli S, Akova M, Boekhout T, Caira M, Guinea J, Chakrabarti A, Dannaoui E, van Diepeningen A, Freiberger T, Groll AH, Hope WW, Johnson E, Lackner M, Lagrou K, Lanternier F, Lass-Florl C, Lortholary O, Meletiadis J, Munoz P, Pagano L, Petrikkos G, Richardson MD, Roilides E, Skiada A, Tortorano AM, Ullmann AJ, Verweij PE, Cornely OA, Cuenca-Estrella M; European Society of Clinical Microbiology and Infectious Diseases Fungal Infection Study Group, European Confederation of Medical Mycology. 2014. ESCMID and ECMM joint clinical guidelines for the diagnosis and management of systemic phaeohyphomycosis: diseases caused by black fungi. Clin Microbiol Infect 20(Suppl 3):S47-S75. http://dx.doi.org/10.1111/1469-0691.12515.
14. Trinh JV, Steinbach WJ, Schell WA, Kurtzberg J, Giles SS, Perfect JR. 2003. Cerebral phaeohyphomycosis in an immunodeficient child treated medically with combination antifungal therapy. Med Mycol 41:339-345. http://dx.doi.org/10.1080/369378031000137369.
15. Levin TP, Baty DE, Fekete T, Truant AL, Suh B. 2004. Cladophialophora bantiana brain abscess in a solid-organ transplant recipient: case report and review of the literature. J Clin Microbiol 42:4374-4378. http://dx.doi.org/10.1128/JCM.42.9.4374-4378.2004.
16. Garzoni C, Markham L, Bijlenga P, Garbino J. 2008. Cladophialophora bantiana: a rare cause of fungal brain abscess. Clinical aspects and new therapeutic options. Med Mycol 46:481-486. http://dx.doi.org/10.1080/13693780801914906.
17. Matsumoto T, Matsuda T, McGinnis MR, Ajello L. 1993. Clinical and mycological spectra of Wangiella dermatitidis infections. Mycoses 36:145-155.
18. Delfino D, De Hoog S, Polonelli L, Benecchi M, Fanti F, Galatioto S, Manti G, Cusumano V. 2006. Survival of a neglected case of brain abscess caused by Cladophialophora bantiana. Med Mycol 44:651-654. http://dx.doi.org/10.1080/13693780600637690.
19. Lyons MK, Blair JE, Leslie KO. 2005. Successful treatment with voriconazoleoffungal cerebral abscess due toCladophialophora bantiana. Clin Neurol Neurosurg 107:532-534. http://dx.doi.org/10.1016/j.clineuro.2004.11.020.
20. Mukherjee PK, Sheehan DJ, Hitchcock CA, Ghannoum MA. 2005. Combination treatment of invasive fungal infections. Clin Microbiol Rev 18:163-194. http://dx.doi.org/10.1128/CMR.18.1.163-194.2005.
21. Lewis RE, Kontoyiannis DP. 2001. Rationale for combination antifungal therapy. Pharmacotherapy 21:149S-164S. http://dx.doi.org/10.1592/phco.21.12.149S.34505.
22. Day JN, Chau TT, Wolbers M, Mai PP, Dung NT, Mai NH, Phu NH, Nghia HD, Phong ND, Thai CQ, Thai LH, Chuong LV, Sinh DX, Duong VA, Hoang TN, Diep PT, Campbell JI, Sieu TP, Baker SG, Chau NV, Hien TT, Lalloo DG, Farrar JJ. 2013. Combination antifungal therapy for cryptococcal meningitis. N Engl J Med 368:1291-1302. http://dx.doi.org/10.1056/NEJMoa1110404.
23. Bennett JE, Dismukes WE, Duma RJ, Medoff G, Sande MA, Gallis H, Leonard J, Fields BT, Bradshaw M, Haywood H, McGee ZA, Cate TR, Cobbs CG, Warner JF, Alling DW. 1979. A comparison of amphotericin B alone and combined with flucytosine in the treatment of cryptococcal meningitis. N Engl J Med 301:126-131. http://dx.doi.org/10.1056/NEJM197907193010303.
24. Perfect JR, Dismukes WE, Dromer F, Goldman DL, Graybill JR, Hamill RJ, Harrison TS, Larsen RA, Lortholary O, Nguyen MH, Pappas PG, Powderly WG, Singh N, Sobel JD, Sorrell TC. 2010. Clinical practice guidelines for the management ofcryptococcal disease: 2010 update bythe Infectious Diseases Society of America. Clin Infect Dis 50:291-322. http://dx.doi.org/10.1086/649858.
25. de Hoog GS, Guarro J, Gene J, Figueras MJ. 2009. Atlas of clinical fungi: the ultimate benchtool for diagnostics, a pilot version of the 3rd ed. CD-ROM. Centraalbureau voor Schimmelcultures, Baarn, The Netherlands.
26. Seyedmousavi S, Netea MG, Mouton JW, Melchers WJ, Verweij PE, de Hoog GS. 2014. Black yeasts and their filamentous relatives: principles of pathogenesis and host defense. Clin Microbiol Rev 27:527-542. http://dx.doi.org/10.1128/CMR.00093-13.
27. CLSI. 2008. Reference method for broth dilution antifungal susceptibility testing of filamentous fungi; approved standard, 2nd ed. CLSI document M38-A2, vol 28, no. 16. Clinical and Laboratory Standards Institute, Wayne, PA.
28. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Use of high inoculum for early metabolic signalling and rapid susceptibility testing of Aspergillus species. J Antimicrob Chemother 59:230-237. http://dx.doi.org/10.1093/jac/dkl488.
29. Antachopoulos C, Meletiadis J, Sein T, Roilides E, Walsh TJ. 2007. Concentration-dependent effectsof caspofungin on the metabolic activity of Aspergillus species. Antimicrob Agents Chemother 51:881-887. http://dx.doi.org/10.1128/AAC.01160-06.
30. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly JP, Verweij PE. 2001. Colorimetric assay for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 39:3402-3408. http://dx.doi.org/10.1128/JCM.39.9.3402-3408.2001.
31. Meletiadis J, Mouton JW, Meis JF, Bouman BA, Donnelly PJ, Verweij PE. 2001. Comparison of spectrophotometric and visual readings of NCCLS method and evaluation of a colorimetric method based on reduction of a soluble tetrazolium salt, 2, 3-bis [2-methoxy-4-nitro-5-[(sulfenylamino) carbonyl]-2H-tetrazolium-hydroxide], for antifungal susceptibility testing of Aspergillus species. J Clin Microbiol 39:4256-4263. http://dx.doi.org/10.1128/JCM.39.12.4256-4263.2001.
32. Seyedmousavi S, Meletiadis J, Melchers WJ, Rijs AJ, Mouton JW, Verweij PE. 2013. In vitro interaction of voriconazole and anidulafungin against triazole-resistant Aspergillus fumigatus. Antimicrob Agents Chemother 57:796-803. http://dx.doi.org/10.1128/AAC.00980-12.
33. Prichard MN, Prichard LE, Shipman C, Jr. 1993. Strategic design and three-dimensional analysis of antiviral drug combinations. Antimicrob Agents Chemother 37:540-545. http://dx.doi.org/10.1128/AAC.37.3.540.
34. Hindler J. 1995. Antimicrobial susceptibility testing, p 5.18.11-15.18.20. In Isenberg HD (ed), Clinical microbiology procedures handbook. American Society for Microbiology, Washington DC.
35. Meletiadis J, Verweij PE, te Dorsthorst DT, Meis JF, Mouton JW. 2005. Assessing in vitro combinations of antifungal drugs against yeasts and filamentous fungi: comparison of different drug interaction models. Med Mycol 43:133-152. http://dx.doi.org/10.1080/13693780410001731547.
36. Meletiadis J, Meis JFGM, Mouton JW, Verweij PE. 2002. Methodological issues related to antifungal drug interaction modelling for filamentous fungi. Rev Med Microbiol 13:101-117.
37. Vitale RG, Afeltra J, de Hoog GS, Rijs AJ, Verweij PE. 2003. In vitro activity of amphotericin B and itraconazole in combination with flucytosine, sulfadiazine and quinolones against Exophiala spinifera. J Antimicrob Chemother 51:1297-1300. http://dx.doi.org/10.1093/jac/dkg218.
38. Meletiadis J, te Dorsthorst DT, Verweij PE. 2006. The concentrationdependent nature of in vitro amphotericin B-itraconazole interaction against Aspergillus fumigatus: isobolographic and response surface analysis of complex pharmacodynamic interactions. Int J Antimicrob Agents 28:439-449. http://dx.doi.org/10.1016/j.ijantimicag.2006.07.011.
39. Tam VH, Schilling AN, Lewis RE, Melnick DA, Boucher AN. 2004. Novel approach to characterization of combined pharmacodynamic effects of antimicrobial agents. Antimicrob Agents Chemother 48:4315-4321. http://dx.doi.org/10.1128/AAC.48.11.4315-4321.2004.
40. Taj-Aldeen SJ, Almaslamani M, Alkhalf A, Al Bozom I, Romanelli AM, Wickes BL, Fothergill AW, Sutton DA. 2010. Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei):a taxonomic update and review of the literature. Med Mycol 48:546-556. http://dx.doi.org/10.3109/13693780903383914.
41. Al-Tawfiq JA, Boukhamseen A. 2011. Cerebral phaeohyphomycosis due to Rhinocladiella mackenziei (formerly Ramichloridium mackenziei): case presentation and literature review. J Infect Public Health 4:96-102. http://dx.doi.org/10.1016/j.jiph.2011.01.001.
42. Chang X, Li R, Yu J, Bao X, Qin J. 2009. Phaeohyphomycosis of the central nervous system caused by Exophiala dermatitidis in a 3-year-old immunocompetent host. J Child Neurol 24:342-345. http://dx.doi.org/10.1177/0883073808323524.
43. Zeng JS, Sutton DA, Fothergill AW, Rinaldi MG, Harrak MJ, de Hoog GS. 2007. Spectrum of clinically relevant Exophiala species in the United States. J Clin Microbiol 45:3713-3720. http://dx.doi.org/10.1128/JCM.02012-06.
44. Hiruma M, Kawada A, Ohata H, Ohnishi Y, Takahashi H, Yamazaki M, Ishibashi A, Hatsuse K, Kakihara M, Yoshida M. 1993. Systemic phaeohyphomycosis caused by Exophiala dermatitidis. Mycoses 36:1-7.
45. Chang CL, Kim DS, Park DJ, Kim HJ, Lee CH, Shin JH. 2000. Acute cerebral phaeohyphomycosis due to Wangiella dermatitidis accompanied by cerebrospinal fluid eosinophilia. J Clin Microbiol 38:1965-1966.
46. Revankar SG, Sutton DA. 2010. Melanized fungi in human disease. Clin Microbiol Rev 23:884-928. http://dx.doi.org/10.1128/CMR.00019-10.
47. Lewis RE. 2011. Current concepts in antifungal pharmacology. Mayo Clinic Proc 86:805-817. http://dx.doi.org/10.4065/mcp. 2011.0247.
48. Polak A. 1987. Combination therapy of experimental candidiasis, cryptococcosis, aspergillosis and wangiellosis in mice. Chemotherapy 33:381-395. http://dx.doi.org/10.1159/000238524.
49. Sun Y, Liu W, Wan Z, Wang X, Li R. 2011. Antifungal activity of antifungal drugs, as well as drug combinations against Exophiala dermatitidis. Mycopathologia 171:111-117. http://dx.doi.org/10.1007/s11046-010-9358-6.